MedTrace Logo

The Effect of Acapella and Incentive Spirometry on Blood Gases and Peak Expiratory Flow Rate After Coronary Artery Bypass Graft.

NCT07337746 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-01-13

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if whether the Acapella and Incentive Spirometry have effect on Blood Gas and Peak Expiratory Flow Rate among patients undergoing Coronary Artery Bypass Graft Surgery. the main question it aims to answer is:

* What is the most effect of using a capella versus incentive spirometry on blood gas parameters (pao2 and paco2) and Peak Expiratory Flow Rate in patient undergoing coronary artery bypass grafting?
* is the incentive spirometry have effect on blood gases parameters and Peak Expiratory Flow Rate?
* is the Acapella have effect on blood gas parameters and Peak Expiratory Flow Rate? Researcher will Compare the Level of Blood gases and Peak Expiratory Flow Rate between Coronary Artery Bypass Graft patients who receive Acapella and Incentive Spirometry and those who do not receive it to see if the Acapella and the Incentive Spirometry work to enhance the level of blood gases parameters and Peak Expiratory Flow Rate.

participant will take Acapella and incentive Spirometry on day before surgery and for three days after Surgery for 10-15 min for each session two times a day.

Conditions

  • Post Opeative Pulmonary Complication

Interventions

DEVICE

Incentive Spirometry therapy

is a device that computes the amount of air that is inspired into the lungs. By causing a piston inside the device to raise when breathing in, an incentive spirometer measures the volume of inspired air.

DEVICE

Acapella therapy

Acapella is a vibration-driven respiratory therapy device that breaks up mucus and promotes airway secretions.

Sponsors & Collaborators

  • University of Baghdad

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
33 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2026-07-01
Completion
2026-08-01

Countries

  • Iraq

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07337746 on ClinicalTrials.gov